CN119173255A - Glp1药物组合物 - Google Patents

Glp1药物组合物 Download PDF

Info

Publication number
CN119173255A
CN119173255A CN202380039380.7A CN202380039380A CN119173255A CN 119173255 A CN119173255 A CN 119173255A CN 202380039380 A CN202380039380 A CN 202380039380A CN 119173255 A CN119173255 A CN 119173255A
Authority
CN
China
Prior art keywords
fluoro
composition
amount
oxadiazol
methylcyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380039380.7A
Other languages
English (en)
Chinese (zh)
Inventor
L·J·伯恩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN119173255A publication Critical patent/CN119173255A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202380039380.7A 2022-05-11 2023-05-10 Glp1药物组合物 Pending CN119173255A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263340591P 2022-05-11 2022-05-11
US63/340591 2022-05-11
PCT/US2023/021637 WO2023220109A1 (en) 2022-05-11 2023-05-10 Glp1 pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CN119173255A true CN119173255A (zh) 2024-12-20

Family

ID=86732348

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380039380.7A Pending CN119173255A (zh) 2022-05-11 2023-05-10 Glp1药物组合物

Country Status (17)

Country Link
US (1) US20250302809A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522129A1 (cg-RX-API-DMAC7.html)
JP (2) JP7767651B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250002778A (cg-RX-API-DMAC7.html)
CN (1) CN119173255A (cg-RX-API-DMAC7.html)
AR (1) AR129296A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023269995A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253043A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003392A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015285A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000232A (cg-RX-API-DMAC7.html)
IL (1) IL316629A (cg-RX-API-DMAC7.html)
JO (1) JOP20240245A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013839A (cg-RX-API-DMAC7.html)
PE (2) PE20260136A1 (cg-RX-API-DMAC7.html)
TW (2) TW202508581A (cg-RX-API-DMAC7.html)
WO (1) WO2023220109A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
KR20260118441A (ko) * 2023-11-21 2026-07-30 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2434641A1 (en) * 2001-01-18 2002-08-22 Pharmacia And Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
AU2007293032A1 (en) * 2006-09-08 2008-03-13 Merck Sharp & Dohme Corp. Liquid pharmaceutical formulations for oral administration of a CGRP antagonist
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
PL3984523T3 (pl) * 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
US11884672B2 (en) * 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7796115B2 (ja) * 2020-09-09 2026-01-08 クリネティックス ファーマシューティカルズ，インク． ソマトスタチン調節因子の製剤
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1

Also Published As

Publication number Publication date
TWI867526B (zh) 2024-12-21
JOP20240245A1 (ar) 2024-11-05
TW202508581A (zh) 2025-03-01
PE20251285A1 (es) 2025-05-14
IL316629A (en) 2024-12-01
WO2023220109A1 (en) 2023-11-16
MX2024013839A (es) 2024-12-06
CA3253043A1 (en) 2023-11-16
JP2026021422A (ja) 2026-02-10
CL2024003392A1 (es) 2025-03-14
AR129296A1 (es) 2024-08-07
TW202410894A (zh) 2024-03-16
PE20260136A1 (es) 2026-01-21
AU2023269995A1 (en) 2024-11-14
US20250302809A1 (en) 2025-10-02
DOP2024000232A (es) 2024-12-30
JP7767651B2 (ja) 2025-11-11
EP4522129A1 (en) 2025-03-19
KR20250002778A (ko) 2025-01-07
JP2025515706A (ja) 2025-05-20
CO2024015285A2 (es) 2024-11-28

Similar Documents

Publication Publication Date Title
TWI867526B (zh) Glp1醫藥組合物
EA028009B1 (ru) Фармацевтическая композиция с улучшенной биодоступностью
US20110136883A1 (en) Granulation of active pharmaceutical ingredients
TW201446286A (zh) 抗病毒化合物之固態分散調製劑
KR20150082203A (ko) 엔잘루타마이드 제제
JP2010509289A (ja) チロシンキナーゼ阻害剤の経口投与用薬学的剤形
WO1999033467A1 (en) Method and composition of an oral preparation of itraconazole
JP2014141518A (ja) 難溶性薬物の溶解性改善製剤
JP2025516547A (ja) Ｇｌｐ１錠剤組成物
US20070071813A1 (en) Novel dosage formulation
KR20190137920A (ko) 엔잘루타미드를 함유하는 경구 투여용 의약 조성물
JP3037393B2 (ja) 経口投与用固形薬剤の製造方法
JP6233911B2 (ja) 化学的な安定性が向上したイルベサルタン含有錠剤
EP2153822A1 (en) Granulation of active pharmaceutical ingredients
JP6199922B2 (ja) 化学的な安定性が向上したイルベサルタン含有錠剤
WO2026019402A1 (en) A pharmaceutical composition comprising nanosuspension of canagliflozin
WO2026019401A1 (en) A nanosuspension composition comprising canagliflozin
WO2024136768A1 (en) Stable pharmaceutical compositions comprising amorphous tolvaptan
AU2023399904A1 (en) Solid dispersion comprising amorphous 2-[3-[4-(1h-indazol-5- ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-yl-acetamide
WO2007102038A1 (en) Ziprasidone formulations
TR2024007612T2 (tr) Amorf tolvaptan i̇çeren formülasyonlar i̇çi̇n i̇yi̇leşti̇ri̇lmi̇ş üreti̇m yöntemi̇
JPWO2020246526A1 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
JP2018009032A (ja) 化学的な安定性が向上したイルベサルタン含有錠剤
TW201247246A (en) Dronedarone solid dispersion and its preparation method
SI22571A (sl) Stabilen trden farmacevtski sestavek, ki obsega kandesartan ali njegove farmacevtsko sprejemljive oblike

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination